Home / Resources / Improving Clinical Outcomes: Leveraging Proprietary Data to Build and Defend Strategies
Improving Clinical Outcomes: Leveraging Proprietary Data to Build and Defend Strategies

What are proprietary data? Proprietary data are any data that cannot be accessed in a public forum. Examples include investigator performance data, site feasibility and recruitment insights, and real-world evidence (RWE) and population data.

Download the white paper.

Preview for the Improving Clinical Outcomes: Leveraging Proprietary Data to Build and Defend Strategies white paper
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.
There is a wealth of information that can materially affect how a site will perform that can only be gleaned through past experiences and on-the-ground intelligence.
Daniel Chancellor, VP, Thought Leadership for Norstella, Citeline’s parent company
Related products
''
Investigator SmartSelect
Quickly generate a list of investigators best fit for your trial
''
Citeline SmartSolutions
Optimize protocol design and study start up with Citeline SmartSolutions, powered by AI
Collage of the various Pharma Ignite marketing capabilities supporting the whole product life cycle.
Real-World Data Solutions
Take a patient-centric view of your clinical trial planning and execution by tapping into a diverse, tokenized real world dataset covering over 300 million US lives.

Related resources

Friendly Doctor His Patient Holding Hands
DEC 18, 2024
Use Case
Clinical

Use case: A Patient-centric Approach to Clinical Trial Site Selection

This use case illustrates how Citeline’s robust datasets, combined with real-world data, inform intelligent clinical trial site and investigator selection.

''
OCT 08, 2024
Press Release

Norstella Introduces NorstellaLinQ, the Biopharma Industry’s First Fully Integrated Data Asset

NorstellaLinQ integrates 74 billion connected data points, paving the way for breakthroughs in drug development and commercialization.

Synthetic Data Generation
SEP 05, 2024
Article
Clinical

The Real Value of Synthetic Data in Clinical Research: 3 Use Cases

Synthetic data, a form of generative AI, focuses on the creation of new content. See three use cases for using synthetic data in clinical research.

View all